How can we mitigate treatment-associated morbidity in patients with germ cell tumors?

Raj R. Bhanvadia; Fady J. Baky; John T. Lafin; Aditya Bagrodia

doi:10.1080/14737140.2021.1932473

How can we mitigate treatment-associated morbidity in patients with germ cell tumors?

Raj R. Bhanvadia, Fady J. Baky, John T. Lafin, Aditya Bagrodia

Research output: Contribution to journal › Editorial › peer-review

Original language	English (US)
Pages (from-to)	805-807
Number of pages	3
Journal	Expert Review of Anticancer Therapy
Volume	21
Issue number	8
DOIs	https://doi.org/10.1080/14737140.2021.1932473
State	Published - 2021

Keywords

Germ cell tumor
RPLND
miRNA
morbidity
systemic chemotherapy
testicular cancer

ASJC Scopus subject areas

Oncology
Pharmacology (medical)

Access to Document

10.1080/14737140.2021.1932473

Cite this

@article{97a8a81c20874e1da8d08cef8f719f72,

title = "How can we mitigate treatment-associated morbidity in patients with germ cell tumors?",

keywords = "Germ cell tumor, RPLND, miRNA, morbidity, systemic chemotherapy, testicular cancer",

author = "Bhanvadia, {Raj R.} and Baky, {Fady J.} and Lafin, {John T.} and Aditya Bagrodia",

note = "Funding Information: This paper was not funded",

year = "2021",

doi = "10.1080/14737140.2021.1932473",

language = "English (US)",

volume = "21",

pages = "805--807",

journal = "Expert Review of Anticancer Therapy",

issn = "1473-7140",